melior melior discovery melior pharmaceuticals preclinical services pre-clinical services in vivo pharmacology in vivo efficacy efficacy models pharmacokinetics indications discovery specialized animal models bioanalytical services theratrace exton pennsylvania cro contract research drug discovery drug development metabolic disease alzheimer’s alzheimers diabetes reprofiling
Melior Discovery
home
Therapeutic Areas
Safety Assessment
 

theraTRACE

Melior Pharmaceuticals

            

                    

 

                   

 

             

 

                 

melior melior melior discovery melior pharmaceuticals preclinical services pre-clinical services in vivo pharmacology in vivo efficacy efficacy models pharmacokinetics indications discovery specialized animal models bioanalytical services theratrace exton pennsylvania cro contract research drug discovery drug development metabolic disease alzheimer’s alzheimers diabetes reprofiling

Melior Discovery pulmonary

Respiratory Depression Assay
Respiratory depression is a significant side effect associated with opioid treatment of acute and chronic pain.  Efforts to generate analgesics that dissociate pain relief from negative side effects are critical. This study examines the effects of morphine in a respiratory depression assay using pulse oximetry. Blood oxygen saturation levels were assessed in conscious rats. Prior to dosing a 30 minute baseline was established for each animal. After dosing, a 5-second average of the oxygen saturation value was sampled every 5 minutes for 60 minutes.

                        

 

 

A significant reduction in O2 saturation was found in rats treated with morphine compared to rats treated with vehicle. Data are mean ± SEM; **p<0.01 compared to vehicle.

 

 

If you are interested in learning more about Respiratory Depression, please contact models@meliordiscovery.com to start the conversation.